Rexahn Announces Reverse Stock Split

Apr 10, 2019

Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting

Mar 27, 2019

Rexahn Pharmaceuticals Reports 2018 Financial Results

Mar 8, 2019

Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients

Mar 4, 2019

Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors

Mar 1, 2019

Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

Feb 19, 2019

Rexahn Announces Presentations at the 2019 ASCO Genitourinary Cancers Symposium

Feb 6, 2019

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types

Feb 4, 2019

Rexahn Announces Pricing of Public Offering of Common Stock and Warrants

Jan 23, 2019

Rexahn Announces Proposed Public Offering of Common Stock and Warrants

Jan 22, 2019